Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Lineage Cell Therapeutics (LCTX) Shares Outstanding (Diluted Average) (2016 - 2025)

Lineage Cell Therapeutics (LCTX) has 12 years of Shares Outstanding (Diluted Average) data on record, last reported at $230.1 million in Q4 2025.

  • For Q4 2025, Shares Outstanding (Diluted Average) rose 14.95% year-over-year to $230.1 million; the TTM value through Dec 2025 reached $230.1 million, up 14.95%, while the annual FY2025 figure was $230.1 million, 14.95% up from the prior year.
  • Shares Outstanding (Diluted Average) reached $230.1 million in Q4 2025 per LCTX's latest filing, up from $228.9 million in the prior quarter.
  • Across five years, Shares Outstanding (Diluted Average) topped out at $230.1 million in Q4 2025 and bottomed at $158725.0 in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $176.8 million, with a median of $172.7 million recorded in 2023.
  • The widest YoY moves for Shares Outstanding (Diluted Average): up 107253.79% in 2021, down 99.89% in 2021.
  • A 5-year view of Shares Outstanding (Diluted Average) shows it stood at $163.1 million in 2021, then increased by 4.09% to $169.8 million in 2022, then rose by 1.69% to $172.7 million in 2023, then grew by 15.94% to $200.2 million in 2024, then grew by 14.95% to $230.1 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Outstanding (Diluted Average) were $230.1 million in Q4 2025, $228.9 million in Q3 2025, and $227.2 million in Q2 2025.